There is currently not enough data to support surveillance or preventive treatment for non-serous OC in PHTS patients and further research is needed such as tumor sequencing to assess the role of PTEN in pathogenesis of non-serous OC in PHTS patients along with further studies to establish lifetime risks and usefulness of surveillance. The gene discussed is PTEN; the disease is PTEN hamartoma tumor syndrome.